bb2121 Adds Nearly 1 Year of PFS for Heavily Pretreated Myeloma

Noopur Raje, MD

The anti-BCMA CAR T-cell therapy bb2121 had a median progression-free survival (PFS) of 11.8 months and a median duration of response of 10.8 months for patients with relapsed/refractory heavily pretreated multiple myeloma, according to updated findings from the multicenter phase I CRB-401 study presented at the 2018 ASCO Annual Meeting.

At the March 29, 2018, data cutoff for the trial, the median follow-up for patients treated with a >150 x 10⁶ dose was 194 days. At this point, the complete response (CR) or stringent CR rate was 50%, with an additional 36.4% of patients having a very good partial response (VGPR). The objective response rate (ORR) was 95.5%. In contrast, those treated with an inactive dose (50 x 10⁶) had an ORR of 33.3% and a 1.9-month median duration of response.

Responses to bb2121 were seen regardless of BCMA expression levels for patients treated with a 450 x 10⁶ dose. In those with low BCMA expression, the ORR was 100% at a median of 168 days of follow-up. The sCR/CR rate in this group was 37.5% and the VGPR was 50%. In those with high BCMA expression, the ORR was 91% after 311 days of follow-up. The sCR/CR rate was 54.5% and the VGPR rate was 27.3%.

"bb2121 at active doses induces deep and durable responses in heavily pretreated multiple myeloma patients," said lead author Noopur Raje, MD, director Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center. "It didn't matter if you had low or high BCMA expression, patients still responded, and the majority of plasma cells do express BCMA."

In the first portion of the study, patients received bb2121 in doses ranging from 50 x 10⁶ to 800 x 10⁶ (N = 21). In a subsequent dose expansion stage, an additional 22 patients received bb2121 at 150 to 450 × 10⁶ CAR+ T cells. Prior to infusion of the CAR T-cell therapy, patients received conditioning with fludarabine (30 mg/m²) and cyclophosphamide (300 mg/m²).

In the dose escalation stage, all patients tested positive for BCMA expression. In the dose expansion phase, patients with low expression (<50%; n = 10) and high expression (≥50%; n = 12) were included. The median follow-up for the escalation stage was 345 days compared with 87 days in the expansion arm.

All 16 evaluable responding patients were negative for minimal residual disease (MRD). In this group, the median PFS was 17.7 months. "MRD-negativity in the bone marrow was seen very early on, as early on as a month," noted Raje. In 2 patients without a response, both tested MRD-positive. In the nonresponding group, the median PFS was 2.7 months.

When looking at persistence of the bb2121 CAR+ T cells, the vector was detectable at 6 months for 44% of patients (n = 7). By month 12, the vector was detectable for 20% of patients (n = 2). Peak expansion numbers were higher in responding patients compared with nonresponders (P = .005).

"A dose response relationship was observed across all active doses, and we did see higher CAR T cell expansion in patients who were responders versus nonresponders," Raje said.

The most common grade ≥3 treatment-emergent adverse events (TEAE) of interest for bb2121 were neutropenia (79%), thrombocytopenia (51%), anemia (44%), cytokine release syndrome (CRS; 5%), and neurotoxicity (2%). Low-grade CRS occurred in 63% of patients and low-grade neurotoxicity was apparent in 33% of bb2121-treated patients.

Most TEAEs were treatable and resolved rapidly. By day 32, absolute neutrophil counts increased to ≥1000/μL for 78% of patients. Platelet counts recovered to ≥50,000/μL for 55% of patients by day 32. There were no grade 4 CRS events and no fatal CRS or neurotoxicity events. Tocilizumab was required for 21% of patients had corticosteroids were administered for 9% of patients.

"Interestingly enough, we found that this product is extremely well tolerated," said Raje. "We did see CRS in almost 60% of patients, but most of it was managed and it was grade 1 and 2 with very little grade 3 CRS, and we just had 1 patient with grade 4 neurotoxicity who is now completely recovered."

Based on an earlier assessment of the dose escalation trial, bb2121 was granted a breakthrough therapy designation in November 2017. A global phase II trial, known as KarMMa, is currently open for enrollment, and will serve as the basis for a regulatory submission for bb2121. The trial plans to enroll 94 patients with relapsed/refractory multiple myeloma (NCT03361748).

"Additional trials are planned for multiple myeloma [in earlier settings]. We have now shown the proof-of-concept in these very end-stage myeloma patients," said Raje. "We are doing ongoing studies looking at predictors of response, to see if there are biomarkers to predict toxicity and to see who the patients are who progress and what the mechanisms of those progressions are."

Raje NS, Berdeja JG, Lin Y, et al. bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study. J Clin Oncol. 2018;36 (suppl; abstr 8007).

<<< 2018 ASCO Annual Meeting

The median age of patients in the escalation stage was 58 years (range, 37-74), and 38% had high-risk cytogenetics. In the expansion group, the median age was 65 years and high-risk cytogenetics were present for 41% of patients. Patients had received 7 and 8 prior therapies, in the escalation and expansion groups, respectively. Twenty-nine percent and 32% of those in the escalation and expansion groups, respectively, were penta-refractory.